Trauma Resuscitation 2026: Damage Control and Massive Transfusion Protocols

Executive Summary

Trauma remains the leading cause of death for Americans aged 1-44, with hemorrhage accounting for 30-40% of trauma mortality. The past decade has seen revolutionary changes in trauma resuscitation, moving from crystalloid-heavy approaches to balanced, blood-product-focused strategies that improve survival in severely injured patients.

The Lethal Triad

Understanding the lethal triad is fundamental to trauma resuscitation:

1. Hypothermia (Core Temperature <35°C/95°F)

• Mechanism: Impairs coagulation cascade enzyme function
• Impact: Each 1°C drop below 35°C increases mortality by 10%
• Prevention: Warm fluids, forced-air warming, increase room temperature to 80-85°F
• Target: Maintain core temperature >36°C (96.8°F)

2. Acidosis (pH <7.2, Base Deficit >6)

• Mechanism: Tissue hypoperfusion → anaerobic metabolism → lactic acidosis
• Impact: Impairs cardiac contractility and coagulation
• Management: Restore perfusion (not bicarbonate), control hemorrhage
• Target: pH >7.25, lactate <4 mmol/L

3. Coagulopathy

• Acute traumatic coagulopathy: Present in 25% of trauma patients on arrival
• Mechanism: Tissue injury, shock, dilution, hypothermia, acidosis
• Management: Early blood products, TXA, avoid crystalloid dilution
• Target: INR <1.5, fibrinogen >150 mg/dL, platelets >50,000/μL

Damage Control Resuscitation (DCR)

Core Principles

1. Permissive Hypotension

Concept: Avoid aggressive fluid resuscitation that increases bleeding before hemorrhage control

Target Blood Pressures:

• Penetrating torso trauma: SBP 80-90 mmHg (MAP 50-60)
• Blunt trauma: SBP 90-100 mmHg (MAP 60-65)
• TBI present: SBP ≥100 mmHg (MAP ≥80) to maintain cerebral perfusion
• Elderly (>65): Higher targets (SBP ≥110) due to impaired autoregulation

Duration: Only until hemorrhage control achieved (surgery, angioembolization)

2. Hemostatic Resuscitation

Principle: Replace blood with blood products, not crystalloid

Massive Transfusion Protocol (MTP) Ratios:

• PROPPR Trial (2015): 1:1:1 ratio (RBC:FFP:Platelets) vs 1:1:2
• Result: No mortality difference, but 1:1:1 achieved hemostasis faster
• Current Standard: 1:1:1 ratio for massive transfusion

3. Minimize Crystalloid

• Problem: Crystalloid dilutes clotting factors, worsens coagulopathy, causes edema
• Guideline: Limit crystalloid to <1 liter in first hour
• Exception: May need more if blood products delayed, but transition to blood ASAP

Whole Blood Resuscitation

The Return of Whole Blood

After decades of component therapy, whole blood is making a comeback:

Advantages

• Physiologic: Contains all blood components in natural ratios
• Practical: Single product vs multiple components
• Logistical: Easier to transport, store, administer
• Clinical: Improved outcomes in military and civilian studies

Types of Whole Blood

Low-Titer O Whole Blood (LTOWB):

• Type O blood with low anti-A and anti-B antibody titers
• Universal donor for trauma resuscitation
• Can be given to any patient regardless of blood type
• Shelf life: 35 days (vs 5 days for platelets)

Fresh Whole Blood (FWB):

• Collected <24 hours before use
• Walking blood bank programs
• Used in military settings, some civilian trauma centers

Current Use

• Over 70% of Level 1 trauma centers now stock LTOWB
• Typically used as initial resuscitation before MTP activation
• Some centers use exclusively for massive transfusion

Tranexamic Acid (TXA)

Mechanism

Antifibrinolytic agent that prevents clot breakdown by inhibiting plasminogen activation

Evidence Base

CRASH-2 Trial (2010):

• 20,211 trauma patients with significant bleeding
• TXA reduced all-cause mortality by 1.5% (14.5% vs 16.0%)
• Greatest benefit when given within 3 hours of injury
• No benefit (possible harm) if given >3 hours post-injury

CRASH-3 Trial (2019) - TBI:

• Mild-moderate TBI: TXA reduced head injury deaths
• Severe TBI: No benefit

Current Recommendations

Indications:

• Hemorrhagic shock from trauma
• Suspected or confirmed significant bleeding
• Within 3 hours of injury

Dosing:

• Loading dose: 1 gram IV over 10 minutes
• Maintenance: 1 gram IV over 8 hours
• Alternative: 2 grams IV bolus (prehospital, austere settings)

Contraindications:

• Known thromboembolic event in past 6 months
• Seizure disorder (relative contraindication)
• >3 hours post-injury (no benefit, possible harm)

REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta)

Concept

Endovascular balloon catheter placed in the aorta to temporarily occlude blood flow, controlling hemorrhage below the occlusion site while maintaining perfusion to heart and brain.

Zones of Deployment

• Zone I (Descending thoracic aorta): For abdominal/pelvic hemorrhage
• Zone II (Visceral aorta): Generally avoided due to visceral ischemia risk
• Zone III (Infrarenal aorta): For pelvic hemorrhage

Indications

• Non-compressible torso hemorrhage with hemodynamic instability
• Pelvic fracture with ongoing bleeding despite pelvic binder
• Bridge to definitive hemorrhage control (surgery, angioembolization)
• Cardiac arrest from hemorrhagic shock (Zone I occlusion)

Contraindications

• Aortic injury (relative)
• Severe atherosclerotic disease
• Uncontrolled hemorrhage above diaphragm

Procedure

1. Access: Common femoral artery (percutaneous or cutdown)
2. Catheter: 7Fr sheath, REBOA catheter advanced under fluoroscopy (or blind with external landmarks)
3. Placement: Zone I (xiphoid) or Zone III (umbilicus) based on injury
4. Inflation: Inflate balloon until distal pulse lost or BP improves
5. Duration: Minimize occlusion time (<60 minutes ideal, <90 minutes maximum)

Complications

• Limb ischemia: Most common (10-15%)
• Distal organ ischemia: Kidneys, bowel, spinal cord
• Balloon rupture: Rare but catastrophic
• Aortic injury: Dissection, perforation

Outcomes Data

Recent studies show:

• Survival benefit in select patients (Zone III for pelvic hemorrhage)
• No clear benefit for Zone I in civilian trauma (high complication rate)
• Best outcomes when used as bridge to angioembolization
• Requires trained operators and institutional protocols

Laboratory Monitoring

Initial Labs (Trauma Bay)

• CBC: Hemoglobin, hematocrit, platelets
• Coagulation: PT/INR, PTT, fibrinogen
• Chemistry: Lactate, base deficit, ionized calcium
• Blood gas: pH, PaCO2, PaO2
• Type and screen: Blood bank (activate MTP if indicated)

Repeat Labs (During MTP)

• Frequency: After every MTP cycle (6 units PRBCs)
• Critical values: Fibrinogen <150 mg/dL (give cryo), platelets <50,000 (give platelets), ionized calcium <1.0 mmol/L (give calcium)

Viscoelastic Testing (TEG/ROTEM)

Advantages:

• Rapid results (10-15 minutes vs 45-60 for conventional coags)
• Functional assessment of entire coagulation process
• Guides targeted therapy (FFP vs platelets vs cryo vs TXA)

Adoption:

• Now available at 60% of Level 1 trauma centers
• Studies show reduced blood product use and improved outcomes

Special Populations

Traumatic Brain Injury (TBI)

• Blood pressure: Maintain SBP ≥100 mmHg (MAP ≥80) for cerebral perfusion
• Avoid hypotension: Single episode of SBP <90 doubles mortality in severe TBI
• Coagulopathy: Common in TBI (30-40%), worsens outcomes
• TXA: Consider in mild-moderate TBI (CRASH-3 data)

Anticoagulated Patients

Warfarin:

• Reverse with 4-factor PCC (preferred) or FFP
• Dose: 25-50 units/kg PCC based on INR
• Add vitamin K 10 mg IV

Direct Oral Anticoagulants (DOACs):

• Dabigatran: Idarucizumab (Praxbind) 5 grams IV
• Xa inhibitors (rivaroxaban, apixaban): Andexanet alfa (Andexxa) or 4-factor PCC

Antiplatelet Agents:

• No specific reversal agent
• Platelet transfusion if active bleeding
• Consider DDAVP 0.3 mcg/kg IV

Elderly Patients

• Higher mortality: Age >65 doubles mortality for same injury
• Occult shock: May not show tachycardia due to beta-blockers or cardiac disease
• Higher BP targets: SBP ≥110 mmHg due to impaired autoregulation
• Anticoagulation common: 30-40% on anticoagulants or antiplatelets

Damage Control Surgery

Indications

• Hemodynamic instability despite resuscitation
• Hypothermia <34°C
• Coagulopathy (clinical bleeding, abnormal labs)
• Acidosis pH <7.2
• Massive transfusion (>10 units PRBCs)

Principles

1. Control hemorrhage: Packing, ligation, shunts (not definitive repair)
2. Control contamination: Staple bowel, don't do anastomoses
3. Temporary closure: Vacuum-assisted closure, don't close fascia
4. ICU resuscitation: Warm, correct coagulopathy, optimize physiology
5. Return to OR: 24-48 hours for definitive repair

Common Pitfalls

Pitfall #1: Over-Resuscitation with Crystalloid

Problem: "Dilutional coagulopathy" from excessive crystalloid

Solution: Limit crystalloid to <1L, transition to blood products early

Pitfall #2: Delayed MTP Activation

Problem: Waiting for labs or "seeing how they respond" before activating MTP

Solution: Activate MTP early based on clinical assessment (ABC score, shock index)

Pitfall #3: Ignoring Calcium

Problem: Citrate in blood products binds calcium, causing hypocalcemia and cardiac dysfunction

Solution: Give 1 gram calcium chloride after every 4-6 units of blood products

Pitfall #4: Forgetting TXA Time Window

Problem: Giving TXA >3 hours post-injury (no benefit, possible harm)

Solution: Document time of injury, give TXA early or not at all

Key Takeaways

1. Damage control resuscitation saves lives: Permissive hypotension, hemostatic resuscitation, minimize crystalloid
2. 1:1:1 ratio is standard: Equal parts RBCs, FFP, and platelets for massive transfusion
3. Whole blood is back: LTOWB simplifies resuscitation and improves outcomes
4. TXA works if given early: Within 3 hours of injury, 1 gram loading dose
5. REBOA is a bridge: Temporary hemorrhage control, not definitive treatment
6. Avoid the lethal triad: Keep patient warm, correct acidosis, fix coagulopathy
7. Activate MTP early: Don't wait for labs, use clinical judgment
8. Monitor calcium: Replace after every 4-6 units of blood products

References

1. Holcomb JB, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471-482.
2. CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32.
3. Sperry JL, et al. Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock. N Engl J Med. 2018;379(4):315-326.
4. Joseph B, et al. Nationwide Analysis of Resuscitative Endovascular Balloon Occlusion of the Aorta in Civilian Trauma. JAMA Surg. 2019;154(6):500-508.
5. Spinella PC, et al. Whole blood for hemostatic resuscitation of major bleeding. Transfusion. 2016;56 Suppl 2:S190-S202.